Filing Flows › Core Scientific, Inc./tx (CORZ) › Q3 2026 › vs Q2 2026
Core Scientific, Inc./tx (CORZ) Q3 2026 vs Q2 2026 (quarter over quarter)
Core Scientific, Inc./tx's revenue rose $68.7M (+42%) from $164M in Q2 2026 to $233M in Q3 2026. Gross margin 52.9% against 42.7% (+10.3 pts).
Core Scientific, Inc./tx, Q3 2026: revenue $233M (+187% year over year), operating margin 31.1%, net earnings $1.2B, operating cash flow $65.3M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 52.9% | 42.7% | +10.3 pts |
| Operating margin | 31.1% | -47.8% | +78.9 pts |
| Net margin | 505.9% | -703.6% | +1209.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $233M | $164M | $68.7M | +42% |
| Gross profit | $123M | $70.0M | $53.2M | +76% |
| Cost of revenue | $110M | $94.2M | $15.4M | +16% |
| Other income, net | $999M | −$1.1B | $2.1B | — |
| Operating profit | $72.3M | −$78.5M | $151M | — |
| Operating expenses | $50.9M | $149M | −$97.6M | -66% |
| Pre-tax earnings | $1.1B | −$1.2B | $2.2B | — |
| SG&A | $45.6M | $49.4M | −$3.8M | -8% |
| Other operating costs | $5.4M | $99.1M | −$93.8M | -95% |
| Income tax benefit | $107M | −$1.9M | $108M | — |
| Net earnings | $1.2B | −$1.2B | $2.3B | — |
| Depreciation & amortization | $18.0M | $15.5M | $2.5M | +16% |
| Share-based compensation | $25.2M | $18.2M | $6.9M | +38% |
| Working capital & other | $1.2B | −$1.1B | $2.3B | — |
| Operating cash flow | $65.3M | −$18.9M | $84.2M | — |
| Capital expenditures | $541M | $565M | −$24.3M | -4% |
| Negative free cash flow (OCF − capex) | $475M | $584M | −$109M | -19% |
Questions
How much did Core Scientific, Inc./tx's revenue grow quarter over quarter in Q3 2026?
Core Scientific, Inc./tx's revenue rose $68.7M (+42%) from $164M in Q2 2026 to $233M in Q3 2026. Gross margin 52.9% against 42.7% (+10.3 pts).